Nuvation Bio develops oral cancer drugs, led by IBTROZI for a form of advanced lung cancer, and is based in New York. NUVB reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 3 dark pool prints.
Prices, price targets and earnings estimates for NUVB are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NUVB is in one of them and how their past NUVB trades turned out.
Nuvation Bio is an oncology company that develops cancer medicines in the form of small molecules, which are chemically designed drugs taken by mouth. Its main approved product, IBTROZI, treats adults with a form of advanced lung cancer that has a specific genetic change. Its other lead program, safusidenib, is being tested for a type of brain tumor called astrocytoma. The company is based in New York, and its partners sell the lung cancer treatment in Japan and China.
